EEF1A2 and ovarian serous adenocarcinoma: To this end, the studies herein demonstrated on-target effects of our human anti-STn-ADC, reduced viability in a subset of high grade serous ovarian cancer (HGSOC) treatment-resistant OvCa PDOs and in PDXs originating from patients diagnosed with HGSOC with a range of STn expression.